<DOC>
	<DOCNO>NCT01911039</DOCNO>
	<brief_summary>Chronic graft versus host disease ( cGVHD ) common complication bone marrow hematopoietic cell transplant another person ( allogeneic transplant ) . This study determine subject steroid dependent/refractory cGVHD tolerate infusion donor regulatory T cell whether cGVHD respond infusion .</brief_summary>
	<brief_title>Phase 1 Infused Donor T Regulatory Cells Steroid Dependent/Refractory Chronic GVHD</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : Determine safety tolerability donor T regulatory ( Treg ) cell infusion subject steroid dependent/refractory chronic graft versus host disease . SECONDARY OBJECTIVES : 1 . Determine quantitative blood Treg cell change follow cell infusion 2 . Determine clinical efficacy donor Treg cell failure-free survival ( FFS ) define absence new immunosuppressive therapy add , non-relapse mortality , recurrent malignancy Day 180 first Treg infusion 3 . In addition FFS , study measure change : 1. cGVHD symptom burden measure Lee cGVHD Symptom Scale increase &gt; 7 point 2 . NIH organ-specific cGVHD scale 3 . The reduction daily corticosteroid requirement prednisone &lt; =0.25 mg/kg-day Day 180 first Treg infusion</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Steroid dependent/refractory cGVHD define : Steroid dependent disease : Persistent cGVHD manifestation require glucocorticoid dose &gt; = prednisone 0.25 mg/kg/day ( 0.5 mg/kg orally [ po ] every day ) least 12 week Steroid refractory disease : Progressive cGVHD manifestation despite treatment glucocorticoid dose &gt; = prednisone 0.5 mg/kg/day ( 1 mg/kg po every day ) least 4 week Participants must receive systemic glucocorticoid therapy cGVHD ; immunosuppressive therapy may include limited tacrolimus , sirolimus , CellCept , cyclosporine , systemic corticosteroid must stable dos 28 day prior first cell infusion Chronic GVHD manifestation follow physical laboratory exam ; include necessarily limit : Skin change Oral mucosa change Bronchiolitis obliterans Ocular change Karnofsky performance status &gt; = 60 Serum creatinine = &lt; 2 mg/dL Absolute neutrophil count ( ANC ) &gt; 1 x 10^9/L Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 20 x upper limit normal ( ULN ) Total bilirubin = &lt; 10 x ULN Allogeneic hematopoietic cell transplant recipient Transfusion independent Oxygen saturation exertion maintain &gt; = 88 % room air Does clinically significant , symptomatic uncontrolled heart disease ( e.g. , unstable angina , congestive heart failure , uncontrolled hypertension ) DONOR : Age &gt; = 18 = &lt; 75 year old DONOR : Karnofsky performance status &gt; = 70 % define institutional standard DONOR : Must sibling donor recipient 's blood marrow graft collect original allogeneic transplant human leukocyte antigen ( HLA ) 7/8 8/8 match HLAA , B , C , DRB1 DONOR : Serologies human immunodeficiency virus ( HIV ) antigen ( Ag ) , HIV 1 HIV 2 antibody ( Ab ) , human Tlymphotropic virus type I ( HTLV 1 ) HTLV 2 Ab , hepatitis B surface antigen ( sAg ) polymerase chain reaction positive ( PCR+ ) , hepatitis C Ab PCR+ , Syphilis ( Treponema ) screen HIV 1 hepatitis C nucleic acid testing ( NAT ) collect prior apheresis DONOR : Female donor childbearing potential must negative serum urine betahuman chorionic gonadotropin ( HCG ) test within three week apheresis DONOR : Capable undergoing leukapheresis , adequate venous access , willing undergo insertion central catheter leukapheresis via peripheral vein inadequate DONOR : Donor selection compliance 21 Code Federal Regulations ( CFR ) 1271 Original transplant utilize unrelated donor graft Uncontrolled infection responsive antimicrobial therapy Progressive malignant disease , include posttransplant lymphoproliferative disease unresponsive therapy Second malignancy except skin cancer within last 5 year Received investigational agent = &lt; 28 day Treg infusion Received filgrastim ( GCSF ) treatment within one month enrollment Received donor lymphocyte infusion ( DLI ) hematopoietic cell transplantation ( HCT ) within 3 month enrollment DONOR : Evidence active infection viral hepatitis DONOR : HIV positive DONOR : Pregnant donor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>GVHD</keyword>
	<keyword>cGVHD</keyword>
</DOC>